Etrumadenant
- Generic Name
- Etrumadenant
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H22N8O
- CAS Number
- 2239273-34-6
- Unique Ingredient Identifier
- W0ZE0NT8IF
- Associated Conditions
- -
- Associated Therapies
- -
Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Gulam Manji
- Target Recruit Count
- 60
- Registration Number
- NCT06048484
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-23
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Catherine Spina
- Target Recruit Count
- 23
- Registration Number
- NCT05915442
- Locations
- 🇺🇸
Columbia University Irving Medical Center / NewYork-Presbyterian Hospital, New York, New York, United States
A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT05886634
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT05335941
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult Participants
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05277012
- Locations
- 🇺🇸
Investigational Site, Lincoln, Nebraska, United States
Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Coherus Biosciences, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT05177770
- Locations
- 🇺🇸
START South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
🇺🇸START Mountain Region, Utah Cancer Specialists, West Valley City, Utah, United States
🇨🇦BC Cancer - The Vancouver Centre, Vancouver, British Columbia, Canada
A Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetic Profile of Etrumadenant in Healthy Adult Participants
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05154136
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers
- Conditions
- Interventions
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Jennifer Choe
- Registration Number
- NCT04892875
Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 30
- Registration Number
- NCT04791839
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.
- Conditions
- Interventions
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 227
- Registration Number
- NCT04660812
- Locations
- 🇮🇹
Azienda Ospedaliero Universitaria Careggi-S.O.D. Patologia Medica, Firenze, Italy
🇮🇹Azienda Ospedaliera Niguarda Ca' Granda, Milano, Italy
🇮🇹Instituto Europeo di Oncologia, Milano, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.